Join industry executives in staying informed on the market access and HTA process in Portugal.  1. Price 1.1. How does price control at ex-factory prices work in your country? Ex-factory prices (PVA) are relevant to determine the retail price (PVP) of medicinal products and their maximum legal margins, as below.   1.2. What are the…

Join industry executives in staying informed on the market access and HTA process in Switzerland.  1. Price Control 1.1. How does price control at ex-factory prices work in your country? Price control is regulated in Art. 65d HIO. Triennially, the FOPH reviews whether the medicinal products included in the LS still meet the WZW-requirements (see…

Join industry executives in staying informed on the market access and HTA process in Denmark.  1. Which are the health technology assessment (HTA) evaluation bodies and their responsibilities in your country? The Danish Medicines Council New medicines (or product with new indications) that are intended for the Danish hospital market, must first be assessed by…

Join industry executives in staying informed on the market access and HTA process in Romania.  1. Price Control 1.1. How does price control at ex-factory prices work in your country? In order to obtain the maximum manufacturer price approval, the medicine’s marketing authorization holder should submit an application dossier to the Ministry of Health, including,…

Join industry executives in staying informed on the market access and HTA process in Brazil.  1. Price Control 1.1. How does price control at ex-factory prices work in your country? The Ex-Factory Price (“PF”) is defined by CMED upon application by the company requesting drug marketing authorization, in accordance with the criteria established in CMED…

1. Price Control 1. How does price control at ex-factory prices work in your country? This question may be broken down in two parts: (i) situations in which a medicinal product may be in connection with its reimbursement status/price; and (ii) criteria to determine PVL.   Situations in which a medicinal product may be in…